Back to discover
Drug

Pazopanib

Approved · EMA
Emerging researchLate-stage development

Also known as Votrient, Pazopanibum.

RxNorm714438ChEMBLCHEMBL477772ATCL01EX03UNII7RN5DR86CK
2
Research papers
15
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Clinical trial2026-07-09Results posted · ClinicalTrials.gov

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Clinical trial2026-07-06Results expected Q2 2034 · ClinicalTrials.gov

A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Clinical trial2026-07-02Results expected Q4 2026 · ClinicalTrials.gov

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

Clinical trial2026-06-22Results expected Q1 2027 · ClinicalTrials.gov

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Clinical trial2026-06-17Results posted · ClinicalTrials.gov

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Clinical trial2026-06-01Results posted · ClinicalTrials.gov

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

Clinical trial2026-05-22Results posted · ClinicalTrials.gov

A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT

Clinical trial2026-05-06Results expected Q1 2027 · ClinicalTrials.gov

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Clinical trial2026-03-03Results expected Q4 2031 · ClinicalTrials.gov

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Research2013-08-01The New England journal of medicine

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Research2013-05-09Clinical genitourinary cancer

Approval: Votrient (EMA)

Regulatory2010-06-14EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Pazopanib
Aliases & brands
VotrientPazopanibum
RxNorm CUI
714438
ChEMBL ID
CHEMBL477772
ATC codes
L01EX03
UNII
7RN5DR86CK
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2010-06-14
Latest approval
2010-06-14
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2010-06-14Approval
Approval: Votrient (EMA)
Indication: Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine… Show full indication

Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

169 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
169
registered trials across all phases
LATEST COMPLETION 2026
15
Active studies
8
Recruiting
24
Late-stage (III+)
107
Completed
47
Discontinued
PHASE DISTRIBUTIONn = 169
Early Phase 12Phase 145Phase 1 / 212Phase 286Phase 2 / 34Phase 311Phase 44Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.

Unknown statusPH IVUniversity Medical Center Groningenn=302025

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

CompletedPH IVInstitut Claudius Regaudn=472020

A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

CompletedPH IViOMEDICO AGn=442017

An Open-Label Study to Evaluate the Effects of Ketoconazole and the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Repeat Doses of Pazopanib in Subjects With Solid Tumor Malignancies

CompletedPH IVGlaxoSmithKlinen=342011

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)

Active, not recruitingPH IIIIntensity Therapeutics, Inc.n=3332028

Recent completions

Trials that read out recently, adding to the completed evidence base.

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

CompletedPH II/IIINational Cancer Institute (NCI)n=1402026

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

CompletedPH IIIIncyte Corporationn=1292025

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

CompletedPH IEli Lilly and Companyn=3532023

A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

CompletedPH IIGrupo Espanol de Investigacion en Sarcomasn=962023

A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma - A Substudy to VEG108844

CompletedPH IINovartis Pharmaceuticalsn=3672021

A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment

CompletedPH IINovartis Pharmaceuticalsn=622021

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Clinical genitourinary cancer1
  • The New England journal of medicine1
Leading researchers
  • Arrowsmith ER1
  • Boleti E1
  • Cella D1
  • Choueiri TK1
  • Crane EJ1
  • Crescenzo R1
  • De Giorgi U1
  • de Souza P1
Leading institutions
free-text, unnormalised
  • Memorial Sloan-Kettering Cancer Center1
  • Sarah Cannon Research Institute1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Sunitinib

Studied across 2 of the same disease areas as Pazopanib in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.